Gene or Genome – Page 12 – Talk Bio

Actionable Insights Powered by AI

ICER Report Suggests Significant Price Reduction for Pfizer’s ATTR-CM Drug Tafamidis

6 months ago talkbio0Tagged ATTR-CM, Cost-Effectiveness, CREM gene, ICER, Pricing, tafamidis

Tafamidis, ATTR-CM, ICER, Pricing, Cost-Effectiveness

FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer

6 months ago talkbio0Tagged amgen, G12C mutation, K-ras Oncogene, Lumakras, Metastasis from malignant neoplasm of colon and/or rectum, panitumumab, sotorasib, United States Food and Drug Administration, Vectibix

FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab

HIV Prevention: A Proven Solution Eludes Many Due to Systemic Barriers

7 months ago talkbio0Tagged Access, Community, Health care facility, Health Equity, HIV Prevention, marginalized, Pre-Exposure Prophylaxis, PREP gene, Social stigmata

HIV Prevention, PrEP (Pre-Exposure Prophylaxis), Health Equity, Marginalized Communities, Stigma, Access to Healthcare

Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer

7 months ago talkbio0Tagged Commission approval, European (ethnic group), Inhibitor, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, PARP1 gene, Talzenna, Xtandi

TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

7 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration

Vanqua Bio Advances Experimental Parkinson’s Therapy with VQ-101, Bolsters Leadership Team

7 months ago talkbio0Tagged Accumulation, alpha-Synuclein, Bio, Clinical Trials, GBA gene, GCase, GCase activator, Lysosomal dysfunction, Neurodegenerative Disorders, Parkinson 's disease, Vanqua, VQ-101

Vanqua Bio, VQ-101, Parkinson’s disease, GBA gene mutations, GCase activator, Neurodegenerative diseases, Clinical trials, Lysosomal dysfunction, Alpha-synuclein accumulation

Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials

7 months ago talkbio0Tagged AAVS1 gene, Clinical Trials, gene therapy, glomerular kidney disease, IGA Glomerulonephritis, Kidney Diseases, Nephrotic Syndrome, Podocytes, Purespring, Series B

Purespring Therapeutics, IgAN gene therapy, kidney disease, Series B funding, clinical trials, AAV gene therapy, podocytes, nephrotic syndrome, glomerular kidney disease.

AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy

7 months ago talkbio0Tagged AstraZeneca, Cardiovascular Diseases, Dosage Forms, GZMH gene, Investments, Lipid-lowering therapy, Lp(a ) disruptor, Pharmaceutical Group

AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment

GSK, Sanofi, and CSL Secure $72 Million BARDA Funding to Enhance Bird Flu Vaccine Supply

7 months ago talkbio0Tagged BARDA, bird flu vaccine, CSHL1 gene, public health medicine (field), sanofi, SmithKline Beecham, Vaccines

BARDA funding, bird flu vaccine, GSK, Sanofi, CSL, vaccine supply, public health

Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery

7 months ago talkbio0Tagged agonists, Biotechnology, Drug Discovery, G-Protein-Coupled Receptors, Hypoparathyroidism, IPO, Preclinical, PTH1R gene, Septerna

Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism